SBIR/STTR Research Award
New Platform Technologies for Viral and Therapeutic Evolution Assays
Award amount
$1,492,018Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2017Award details
- Awarding agency
- Department of Defense
- Branch
- Defense Advanced Research Projects Agency
- Recipient company
- SCRIBE BIOSCIENCES, INC.
- Proposal award date
- 2017-09-13
- Contract end date
- 2020-11-20
- UEI
- QMCJSMLF9TP1
- Solicitation number
- 17.1
- Topic code
- SB171-003
Research abstract
There is a critical need for platforms to study long term viral evolution to develop new therapies and asses the efficacy of current treatments. Current flask based serial passaging techniques are discontinuous and often lose low abundance viral mutants....
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- High throughput antibody discovery against cell membrane bound target proteins using innovative MOD technology for direct screening in single-cell assays
- Microenvironment on Demand (MOD): A platform for single-cell cytotoxicity assays
- A platform for engineering peptide ligase for building next generation peptide therapeutics.
- A platform for integratingcell signaling and single cell transcriptomics.
- SBIR Phase I: Controlled Organoid Synthesis with Fluorescence-Activated Cell Printing
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- New Platform Technologies for Viral and Therapeutic Evolution Assays
- Bioreactor for Viral Diseases Assay System
Research funding history
8 SBIR/STTR records share this UEI (2017–2023). Reported award amounts total $3,442,676. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation